Clopidogrel - CAS 113665-84-2
Catalog number: 113665-84-2
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
C16H16ClNO2S
Molecular Weight:
321.82
COA:
Inquire
Targets:
P2Y Receptor
Description:
Clopidogrel, a thienopyridine derivative, could be used in the prevention and treatment of sorts of arterial circulation disorders caused by platelet aggregation.
Purity:
≥98%
Appearance:
Viscous liquid
Synonyms:
Clopidogrel; Plavix; Zyllt; (S)-Clopidogrel; CLOPIDOGREL SULFATE
Solubility:
10 mM in DMSO
Storage:
-20ºC Freeze
MSDS:
Inquire
Application:
Clopidogrel could be used in the prevention and treatment of sorts of arterial circulation disorders caused by platelet aggregation.
Shelf Life:
As supplied, 2 years from the QC date provided on the Certificate of Analysis, when stored properly
Quantity:
Grams-Kilos
Boiling Point:
423.7ºC at 760mmHg
Density:
1.317g/cm3
InChIKey:
GKTWGGQPFAXNFI-HNNXBMFYSA-N
InChI:
InChI=1S/C16H16ClNO2S/c1-20-16(19)15(12-4-2-3-5-13(12)17)18-8-6-14-11(10-18)7-9-21-14/h2-5,7,9,15H,6,8,10H2,1H3/t15-/m0/s1
Canonical SMILES:
COC(=O)C(C1=CC=CC=C1Cl)N2CCC3=C(C2)C=CS3
1.Advanced age and high residual platelet reactivity in patients receiving dual antiplatelet therapy with Clopidogrel or Ticagrelor: reply.
Verdoia M1, De Luca G1. J Thromb Haemost. 2016 Apr 21. doi: 10.1111/jth.13345. [Epub ahead of print]
Optimal inhibition of platelet aggregation, including dual antiplatelet therapy (DAPT), is a pillar treatment for patients experiencing an acute cardiovascular event (2-4). Residual high-on treatment platelet reactivity (HRPR) has been associated with a 2 to 9 fold increased risk of stent thrombosis and recurrent ischemic events, thereby annulling the benefits of DAPT (5,6). Thus, we completely agree with Dr Tang's conclusion that the extreme inter-individual variability in the response to antiplatelet agents deserves to be addressed by the development of tailored antithrombotic strategies. This article is protected by copyright. All rights reserved.
2.A self-assembling matrix-forming gel can be easily and safely applied to prevent delayed bleeding after endoscopic resections.
Pioche M1, Camus M2, Rivory J3, Leblanc S4, Lienhart I3, Barret M2, Chaussade S2, Saurin JC5, Prat F2, Ponchon T1. Endosc Int Open. 2016 Apr;4(4):E415-9. doi: 10.1055/s-0042-102879. Epub 2016 Mar 30.
BACKGROUND: Endoscopic resections have low morbidity and mortality. Delayed bleeding has been reported in approximately 1 - 15 % of cases, increasing with antiplatelet/anticoagulant therapy or portal hypertension. A self-assembling peptide (SAP) forming a gel could protect the mucosal defect during early healing. This retrospective trial aimed to assess the safety and efficacy of SAP in preventing delayed bleeding after endoscopic resections.
3.Impact of concomitant use of proton pump inhibitors and clopidogrel or ticagrelor on clinical outcomes in patients with acute coronary syndrome.
Yan Y1, Wang X1, Fan JY1, Nie SP1, Raposeiras-Roubín S2, Abu-Assi E2, Henriques JP3, D'Ascenzo F4, Saucedo J5, González-Juanatey JR6, Wilton SB7, Kikkert WJ3, Nuñez-Gil I8, Ariza-Sole A9, Song XT1, Alexopoulos D10, Liebetrau C11, Kawaji T12, Moretti C4, Huczek Z13, Fujii T14, Correia LC15, Kawashiri MA16, Kedev S17. J Geriatr Cardiol. 2016 Mar;13(3):209-17. doi: 10.11909/j.issn.1671-5411.2016.03.007.
BACKGROUND: There is great debate on the possible adverse interaction between proton pump inhibitors (PPIs) and clopidogrel. In addition, whether the use of PPIs affects the clinical efficacy of ticagrelor remains less known. We aimed to determine the impact of concomitant administration of PPIs and clopidogrel or ticagrelor on clinical outcomes in patients with acute coronary syndrome (ACS) after percutaneous coronary intervention (PCI).
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related P2Y Receptor Products


CAS 630103-23-0 MRS 2500 tetraammonium salt

MRS 2500 tetraammonium salt
(CAS: 630103-23-0)

MRS 2500 tetraammonium salt is a highly potent and selective antagonist of the platelet P2Y1 receptor (Ki = 0.78 nM). It inhibits ADP-induced aggregation of hum...

CAS 1006028-37-0 NF 546

NF 546
(CAS: 1006028-37-0)

NF 546 is a P2Y11 agonist with pEC50 value of 6.27. It can stimulate release of interleukin-8 from human monocyte-derived dendritic cells.

MRS 2905

MRS 2905 is a potent and selective P2Y14 receptor agonist (EC50 = 0.92 nM), with >2000-fold selectivity over P2Y6.

CAS 274693-27-5 Ticagrelor

Ticagrelor
(CAS: 274693-27-5)

Ticagrelor, the first reversible oral P2Y12 receptor antagonist, provides faster, greater, and more consistent ADP-receptor inhibition than Clopidogrel. Used in...

Clopidogrel thiolactone
(CAS: 1147350-75-1)

The thiolactone form of Clopidogrel that could be an effective antiplatelet agent for behaving as an inhibitor of P2Y12 receptor.

CAS 1266569-94-1 UTPγS trisodium salt

UTPγS trisodium salt
(CAS: 1266569-94-1)

UTPγS trisodium salt is a selective P2Y2 and P2Y4 receptor agonist.

CAS 150322-43-3 Prasugrel

Prasugrel
(CAS: 150322-43-3)

Prasugrel is a thienopyridine prodrug that is converted by esterases to a receptor antagonist for purinergic P2Y12 receptors. The blockade of P2Y12 receptor act...

CAS 1052087-90-7 PSB 0739

PSB 0739
(CAS: 1052087-90-7)

PSB 0739 is a highly potent, direct‐acting and reversible P2Y12 receptor antagonist (Ki = 24.9 nM). Unlike clopidogrel, it does not require bioactivation. P2Y12...

Chemical Structure

CAS 113665-84-2 Clopidogrel

Quick Inquiry

Verification code

Featured Items